comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists of semaglutide for patients type 2 diabetes in clinical practice SGLT2 vs GLP-1: Individualizing Diabetes,

doi: 10.1038/s41591-022-01707-4 78 US National Institutes of Health

North America dominates the market landscape, supported by favorable reimbursement policies, advanced healthcare infrastructure, and high treatment adoption rates

Another contraindication is the use of GLP-1RA in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2 (33, 34, 36)

2% WL with placebo in people with obesity [68]

Side Effects to Know About The most common side effects are digestive: Nausea & Vomiting Diarrhea or constipation Bloating These often improve after the first few weeks as your body adjusts